We treated the panel of colon cancer cells and their isogenic XPC knock-out (KO) counterparts with oxaliplatin and observed that in 6 out of 10 cell lines XPC loss did not lead to increased sensitivity to oxaliplatin (Figure 1A and Supplementary Figure S2a). The gene discussed is XPC; the disease is malignant colon neoplasm.